Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001213900-21-000217
Filing Date
2021-01-04
Accepted
2021-01-04 17:28:28
Documents
2
Period of Report
2020-12-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO FORM 8-K ea132661-8ka1_inmune.htm 8-K/A 75507
2 RIGHTS AGREEMENT, DATED AS OF DECEMBER 30, 2020, BY AND BETWEEN INMUNE BIO INC. ea132661ex4-1_inmune.htm EX-4.1 479899
  Complete submission text file 0001213900-21-000217.txt   556717
Mailing Address 1200 PROSPECT STREET SUITE 525 LA JOLLA CA 92037
Business Address 1200 PROSPECT STREET SUITE 525 LA JOLLA CA 92037 8589643720
Inmune Bio, Inc. (Filer) CIK: 0001711754 (see all company filings)

EIN.: 475205835 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-38793 | Film No.: 21502909
SIC: 2836 Biological Products, (No Diagnostic Substances)